A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome "PLATO"

Completed

Phase 3 Results

Summary of Purpose

Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 10 February 2012.

1 Oct 2006 23 Oct 2006 1 Mar 2009 1 Mar 2009 1 Feb 2012 31 Jan 2011
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions See All

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Study Director: Jonathan C. Fox, MD AstraZeneca Clinical Study, Information 1-800-236-9933

    information.center@astrazeneca.com